BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:28 PM
 | 
Jul 23, 2008
 |  BC Extra  |  Company News

EC specifies K-Ras status for Erbitux

Merck KGaA (Xetra:MRK) said the EC approved Erbitux cetuximab to treat patients with EGFR-expressing, K-Ras (KRAS) wild-type metastatic colorectal cancer in combination with chemotherapy and as a single agent in patients who have failed...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >